# Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

> **NCT00479817** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 161 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** AMG 386
- **DRUG:** AMG 386
- **DRUG:** Paclitaxel
- **DRUG:** AMG 386 Placebo

## Key facts

- **NCT ID:** NCT00479817
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-05
- **Primary completion:** 2009-08-11
- **Final completion:** 2019-12-09
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2019-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479817, "Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00479817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*